Practice Alert Podcast

Reference

1. US Preventive Services Task Force. Final recommendation statement: cognitive impairment in older adults: screening. www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cognitive-impairment-in-older-adults-screening. Published February 2020. Accessed March 19, 2020.

Reference

1. US Preventive Services Task Force. Final recommendation statement: cognitive impairment in older adults: screening. www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cognitive-impairment-in-older-adults-screening. Published February 2020. Accessed March 19, 2020.

Reference

1. US Preventive Services Task Force. Final recommendation statement: cognitive impairment in older adults: screening. www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cognitive-impairment-in-older-adults-screening. Published February 2020. Accessed March 19, 2020.

References

1. Interim Infection Prevention and Control Recommendations for Patients with Confirmed Coronavirus Disease 2019 (COVID-19) or Persons Under Investigation for COVID-19 in Healthcare Settings. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Finfection-control.html. Updated February 21, 2020. Accessed February 27, 2020.
2. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Updated February 12, 2020. Accessed February 27, 2020.
3. Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for 2019 Novel Coronavirus (2019-nCoV). Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-home-care.html. Updated February 12, 2020. Accessed February 27, 2020.
4. Interim Guidance for Preventing the Spread of Coronavirus Disease 2019 (COVID-19) in Homes and Residential Communities. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.html. Updated February 14, 2020. Accessed February 27, 2020.
5. World Health Organization. Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Updated February 26, 2020. Accessed February 27, 2020.
6. Coronavirus Disease 2019 (COVID-19) in the U.S. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html. Updated February 26, 2020. Accessed February 27, 2020.

ALSO, see last month’s audiocast: “Coronavirus outbreak: Putting it into perspective.”

References

1. Interim Infection Prevention and Control Recommendations for Patients with Confirmed Coronavirus Disease 2019 (COVID-19) or Persons Under Investigation for COVID-19 in Healthcare Settings. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Finfection-control.html. Updated February 21, 2020. Accessed February 27, 2020.
2. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Updated February 12, 2020. Accessed February 27, 2020.
3. Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for 2019 Novel Coronavirus (2019-nCoV). Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-home-care.html. Updated February 12, 2020. Accessed February 27, 2020.
4. Interim Guidance for Preventing the Spread of Coronavirus Disease 2019 (COVID-19) in Homes and Residential Communities. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.html. Updated February 14, 2020. Accessed February 27, 2020.
5. World Health Organization. Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Updated February 26, 2020. Accessed February 27, 2020.
6. Coronavirus Disease 2019 (COVID-19) in the U.S. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html. Updated February 26, 2020. Accessed February 27, 2020.

ALSO, see last month’s audiocast: “Coronavirus outbreak: Putting it into perspective.”

References

1. Interim Infection Prevention and Control Recommendations for Patients with Confirmed Coronavirus Disease 2019 (COVID-19) or Persons Under Investigation for COVID-19 in Healthcare Settings. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Finfection-control.html. Updated February 21, 2020. Accessed February 27, 2020.
2. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Updated February 12, 2020. Accessed February 27, 2020.
3. Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for 2019 Novel Coronavirus (2019-nCoV). Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-home-care.html. Updated February 12, 2020. Accessed February 27, 2020.
4. Interim Guidance for Preventing the Spread of Coronavirus Disease 2019 (COVID-19) in Homes and Residential Communities. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.html. Updated February 14, 2020. Accessed February 27, 2020.
5. World Health Organization. Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Updated February 26, 2020. Accessed February 27, 2020.
6. Coronavirus Disease 2019 (COVID-19) in the U.S. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html. Updated February 26, 2020. Accessed February 27, 2020.

ALSO, see last month’s audiocast: “Coronavirus outbreak: Putting it into perspective.”

References

1. Centers for Disease Control and Prevention. 2019 novel coronavirus. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html. Last reviewed February 8, 2020. Accessed February 9, 2020.
2. World Health Organization. Novel coronavirus (2019-nCoV) situation as of 10 February 2020. http://who.maps.arcgis.com/apps/opsdashboard/index.html#/c88e37cfc43b4ed3baf977d77e4a0667. Accessed February 9, 2020.
3. Centers for Disease Control and Prevention. 2019 novel coronavirus: Evaluating and reporting persons under investigation (PUI). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html Last reviewed February 3, 2020. Accessed February 9, 2020.
4. Centers for Disease Control and Prevention. Weekly US influenza surveillance report. https://www.cdc.gov/flu/weekly/index.htm. Last reviewed February 7, 2020. Accessed February 12, 2020.

References

1. Centers for Disease Control and Prevention. 2019 novel coronavirus. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html. Last reviewed February 8, 2020. Accessed February 9, 2020.
2. World Health Organization. Novel coronavirus (2019-nCoV) situation as of 10 February 2020. http://who.maps.arcgis.com/apps/opsdashboard/index.html#/c88e37cfc43b4ed3baf977d77e4a0667. Accessed February 9, 2020.
3. Centers for Disease Control and Prevention. 2019 novel coronavirus: Evaluating and reporting persons under investigation (PUI). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html Last reviewed February 3, 2020. Accessed February 9, 2020.
4. Centers for Disease Control and Prevention. Weekly US influenza surveillance report. https://www.cdc.gov/flu/weekly/index.htm. Last reviewed February 7, 2020. Accessed February 12, 2020.

References

1. Centers for Disease Control and Prevention. 2019 novel coronavirus. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html. Last reviewed February 8, 2020. Accessed February 9, 2020.
2. World Health Organization. Novel coronavirus (2019-nCoV) situation as of 10 February 2020. http://who.maps.arcgis.com/apps/opsdashboard/index.html#/c88e37cfc43b4ed3baf977d77e4a0667. Accessed February 9, 2020.
3. Centers for Disease Control and Prevention. 2019 novel coronavirus: Evaluating and reporting persons under investigation (PUI). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html Last reviewed February 3, 2020. Accessed February 9, 2020.
4. Centers for Disease Control and Prevention. Weekly US influenza surveillance report. https://www.cdc.gov/flu/weekly/index.htm. Last reviewed February 7, 2020. Accessed February 12, 2020.

References

1. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2016. HIV Surveillance Supplemental Report. 2019;24. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published February 2019. Accessed January 17, 2020.
2. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. CDC Web Site. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018. Accessed January 17, 2020.
3. US Preventive Services Task Force. Final recommendation statement: prevention of human immunodeficiency virus (HIV) infection: preexposure prophylaxis. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis. Published June 2019. Accessed January 17, 2020.
4. Campos-Outcalt D. A look at new guidelines for HIV treatment and prevention. J Fam Pract. 2018;67:768-772.

References

1. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2016. HIV Surveillance Supplemental Report. 2019;24. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published February 2019. Accessed January 17, 2020.
2. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. CDC Web Site. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018. Accessed January 17, 2020.
3. US Preventive Services Task Force. Final recommendation statement: prevention of human immunodeficiency virus (HIV) infection: preexposure prophylaxis. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis. Published June 2019. Accessed January 17, 2020.
4. Campos-Outcalt D. A look at new guidelines for HIV treatment and prevention. J Fam Pract. 2018;67:768-772.

References

1. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2016. HIV Surveillance Supplemental Report. 2019;24. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published February 2019. Accessed January 17, 2020.
2. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. CDC Web Site. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018. Accessed January 17, 2020.
3. US Preventive Services Task Force. Final recommendation statement: prevention of human immunodeficiency virus (HIV) infection: preexposure prophylaxis. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis. Published June 2019. Accessed January 17, 2020.
4. Campos-Outcalt D. A look at new guidelines for HIV treatment and prevention. J Fam Pract. 2018;67:768-772.

References

1. Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019;156:218-226.
2. Rao VL, Micic D, Davis AM. Medical management of opioid-induced constipation. JAMA. 2019;322:2241-2242.
3. Naldemedine (Symproic) for opioid-induced constipation. Med Lett Drugs Ther. 2017;59:196-198.
4. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016;65:1-49.

References

1. Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019;156:218-226.
2. Rao VL, Micic D, Davis AM. Medical management of opioid-induced constipation. JAMA. 2019;322:2241-2242.
3. Naldemedine (Symproic) for opioid-induced constipation. Med Lett Drugs Ther. 2017;59:196-198.
4. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016;65:1-49.

References

1. Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019;156:218-226.
2. Rao VL, Micic D, Davis AM. Medical management of opioid-induced constipation. JAMA. 2019;322:2241-2242.
3. Naldemedine (Symproic) for opioid-induced constipation. Med Lett Drugs Ther. 2017;59:196-198.
4. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016;65:1-49.

References

1. Final update summary: breast cancer: medication use to reduce risk. U.S. Preventive Services Task Force Web Site. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-medications-for-risk-reduction1 Updated October 2019. Accessed November 25, 2019.
2. Final update summary: BRCA-related cancer: risk assessment, genetic counseling, and genetic testing. U.S. Preventive Services Task Force Web Site. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1. Updated August 2019. Accessed November 25, 2019.
3. Campos-Outcalt D. USPSTF BRCA testing recs: 2 more groups require attention. J Fam Pract. 2019;68:audio. https://www.mdedge.com/familymedicine/article/208085/womens-health/uspstf-brca-testing-recs-2-more-groups-require-attention?channel=60894. Accessed November 25, 2019.

References

1. Final update summary: breast cancer: medication use to reduce risk. U.S. Preventive Services Task Force Web Site. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-medications-for-risk-reduction1 Updated October 2019. Accessed November 25, 2019.
2. Final update summary: BRCA-related cancer: risk assessment, genetic counseling, and genetic testing. U.S. Preventive Services Task Force Web Site. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1. Updated August 2019. Accessed November 25, 2019.
3. Campos-Outcalt D. USPSTF BRCA testing recs: 2 more groups require attention. J Fam Pract. 2019;68:audio. https://www.mdedge.com/familymedicine/article/208085/womens-health/uspstf-brca-testing-recs-2-more-groups-require-attention?channel=60894. Accessed November 25, 2019.

References

1. Final update summary: breast cancer: medication use to reduce risk. U.S. Preventive Services Task Force Web Site. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-medications-for-risk-reduction1 Updated October 2019. Accessed November 25, 2019.
2. Final update summary: BRCA-related cancer: risk assessment, genetic counseling, and genetic testing. U.S. Preventive Services Task Force Web Site. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1. Updated August 2019. Accessed November 25, 2019.
3. Campos-Outcalt D. USPSTF BRCA testing recs: 2 more groups require attention. J Fam Pract. 2019;68:audio. https://www.mdedge.com/familymedicine/article/208085/womens-health/uspstf-brca-testing-recs-2-more-groups-require-attention?channel=60894. Accessed November 25, 2019.

References

1. Lewis N, McCaffrey K, Sage K, et al. E-cigarette use, or vaping, practices and characteristics among persons with associated lung injury — Utah, April–October 2019. MMWR Morb Mortal Wkly Rep. 2019;68. https://www.cdc.gov/mmwr/volumes/68/wr/mm6842e1.htm?s_cid=mm6842e1_w. Published October 22, 2019. Accessed October 24, 2019.
2. Siegal DA, Jatlaoui TC, Koumans EH, et al. Update: interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use associated lung injury – United States, October 2019. MMWR Morb Mortal Wkly Rep. 2019;68:919-927.
3. Centers for Disease Control and Prevention. Outbreak of lung injury associated with e-cigarette use, or vaping. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html. Updated October 17, 2019. Accessed October 24, 2019.

References

1. Lewis N, McCaffrey K, Sage K, et al. E-cigarette use, or vaping, practices and characteristics among persons with associated lung injury — Utah, April–October 2019. MMWR Morb Mortal Wkly Rep. 2019;68. https://www.cdc.gov/mmwr/volumes/68/wr/mm6842e1.htm?s_cid=mm6842e1_w. Published October 22, 2019. Accessed October 24, 2019.
2. Siegal DA, Jatlaoui TC, Koumans EH, et al. Update: interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use associated lung injury – United States, October 2019. MMWR Morb Mortal Wkly Rep. 2019;68:919-927.
3. Centers for Disease Control and Prevention. Outbreak of lung injury associated with e-cigarette use, or vaping. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html. Updated October 17, 2019. Accessed October 24, 2019.

References

1. Lewis N, McCaffrey K, Sage K, et al. E-cigarette use, or vaping, practices and characteristics among persons with associated lung injury — Utah, April–October 2019. MMWR Morb Mortal Wkly Rep. 2019;68. https://www.cdc.gov/mmwr/volumes/68/wr/mm6842e1.htm?s_cid=mm6842e1_w. Published October 22, 2019. Accessed October 24, 2019.
2. Siegal DA, Jatlaoui TC, Koumans EH, et al. Update: interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use associated lung injury – United States, October 2019. MMWR Morb Mortal Wkly Rep. 2019;68:919-927.
3. Centers for Disease Control and Prevention. Outbreak of lung injury associated with e-cigarette use, or vaping. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html. Updated October 17, 2019. Accessed October 24, 2019.

Reference

1. US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer. JAMA. 2019;322:652-665.

Reference

1. US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer. JAMA. 2019;322:652-665.

Reference

1. US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer. JAMA. 2019;322:652-665.

References

1. Markowitz L. Overview and background (HPV). CDC Web site. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/HPV-2-Markowitz-508.pdf. Presented February 27, 2019. Accessed August 1, 2019.
2. Brisson M, Laprise J-F. Cost-effectiveness of extending HPV vaccination above age 26 years in the U.S. CDC Web site. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/HPV-3-Brisson-508.pdf. Presented February 2019. Accessed August 1, 2019.
3. Markowitz L. Recommendations for mid-adult HPV vaccination work group considerations. CDC Web site. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/HPV-7-Markowitz-508.pdf, Presented February 27, 2019. Accessed August 1, 2019.
4. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702.

References

1. Markowitz L. Overview and background (HPV). CDC Web site. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/HPV-2-Markowitz-508.pdf. Presented February 27, 2019. Accessed August 1, 2019.
2. Brisson M, Laprise J-F. Cost-effectiveness of extending HPV vaccination above age 26 years in the U.S. CDC Web site. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/HPV-3-Brisson-508.pdf. Presented February 2019. Accessed August 1, 2019.
3. Markowitz L. Recommendations for mid-adult HPV vaccination work group considerations. CDC Web site. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/HPV-7-Markowitz-508.pdf, Presented February 27, 2019. Accessed August 1, 2019.
4. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702.

References

1. Markowitz L. Overview and background (HPV). CDC Web site. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/HPV-2-Markowitz-508.pdf. Presented February 27, 2019. Accessed August 1, 2019.
2. Brisson M, Laprise J-F. Cost-effectiveness of extending HPV vaccination above age 26 years in the U.S. CDC Web site. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/HPV-3-Brisson-508.pdf. Presented February 2019. Accessed August 1, 2019.
3. Markowitz L. Recommendations for mid-adult HPV vaccination work group considerations. CDC Web site. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/HPV-7-Markowitz-508.pdf, Presented February 27, 2019. Accessed August 1, 2019.
4. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702.

Reference

1. US Preventive Services Task Force. Draft Evidence Review for Prevention and Cessation of Tobacco Use in Children and Adolescents: Primary Care Interventions. https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review/tobacco-and-nicotine-use-prevention-in-children-and-adolescents-primary-care-interventions. Accessed July 8, 2019.

Reference

1. US Preventive Services Task Force. Draft Evidence Review for Prevention and Cessation of Tobacco Use in Children and Adolescents: Primary Care Interventions. https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review/tobacco-and-nicotine-use-prevention-in-children-and-adolescents-primary-care-interventions. Accessed July 8, 2019.

Reference

1. US Preventive Services Task Force. Draft Evidence Review for Prevention and Cessation of Tobacco Use in Children and Adolescents: Primary Care Interventions. https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review/tobacco-and-nicotine-use-prevention-in-children-and-adolescents-primary-care-interventions. Accessed July 8, 2019.